1. Phosphorylation of Hsp20 Promotes Fibrotic Remodeling and Heart Failure
- Author
-
George Gardner, Evangelia G. Kranias, Guo-Chang Fan, Guan-Sheng Liu, Jiang Qian, Yutian Li, Nathan Robbins, Kobra Haghighi, Jack Rubinstein, Burns C. Blaxall, Min Jiang, and Joshua G. Travers
- Subjects
inorganic chemicals ,0301 basic medicine ,WT, wild type ,STAT3, signal transducer and activator of transcription 3 ,heart failure ,I/R, ischemia/reperfusion ,030204 cardiovascular system & hematology ,environment and public health ,TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling ,fibroblast ,Ccl2, C-C motif chemokine ligand 2 ,03 medical and health sciences ,Paracrine signalling ,PRECLINICAL RESEARCH ,0302 clinical medicine ,Downregulation and upregulation ,In vivo ,TG, transgenic ,Col1a1, collagen 1A1 ,medicine ,Hsp, heat shock protein ,Col3A1, collagen 3A1 ,Fibroblast ,Postn, periostin ,TGF, transforming growth factor ,remodeling ,Hsp20 ,IL-6 ,TNF, tumor necrosis factor ,business.industry ,fungi ,medicine.disease ,3. Good health ,Cell biology ,Blockade ,ECM, extra-cellular matrix ,IL, interleukin ,enzymes and coenzymes (carbohydrates) ,030104 developmental biology ,medicine.anatomical_structure ,Ccl3, C-C motif chemokine ligand 3 ,Heart failure ,bacteria ,Phosphorylation ,SMA, smooth muscle actin ,Cardiology and Cardiovascular Medicine ,business ,Ex vivo - Abstract
Visual Abstract, Highlights • PKA-phosphorylation of Hsp20 is elevated in human failing hearts. • Increases in phosphorylated Hsp20 in vivo are associated with fibrotic remodeling and reduced left ventricular function. • The phosphorylated Hsp20 in cardiomyocyte promotes upregulation of IL-6 and its subsequent paracrine actions on the cardiac fibroblast. • Blockade of IL-6 effects ex vivo and in vivo reduces the pro-fibrotic effects of phosphorylated Hsp20. • Targeting phosphorylated Hsp20 in the cardiomyocyte may represent a potential therapeutic strategy to mitigate fibrotic remodeling and preserve function in the failing heart., Summary Cardiomyocyte-specific increases in phosphorylated Hsp20 (S16D-Hsp20) to levels similar to those observed in human failing hearts are associated with early fibrotic remodeling and depressed left ventricular function, symptoms which progress to heart failure and early death. The underlying mechanisms appear to involve translocation of phosphorylated Hsp20 to the nucleus and upregulation of interleukin (IL)-6, which subsequently activates cardiac fibroblasts in a paracrine fashion through transcription factor STAT3 signaling. Accordingly, treatment of S16D-Hsp20 mice with a rat anti-mouse IL-6 receptor monoclonal antibody (MR16-1) attenuated interstitial fibrosis and preserved cardiac function. These findings suggest that phosphorylated Hsp20 may be a potential therapeutic target in heart failure.
- Published
- 2019